Increased incidence of Sjogren’s syndrome in systemic sclerosis: A nationwide population study

References

• Fransen, J., S. R. Johnson, F. van den Hoogen, et al. (2012). Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise. Arthritis Care Res. (Hoboken) 64: 351–357
   PubMed Web of Science ®Google Scholar
• Hamaguchi, Y. (2010). Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J. Dermatol. 37: 42–53
   PubMed Web of Science ®Google Scholar
• Elhai, M., J. Avouac, A. Kahan, et al. (2013). Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun. Rev. 12: 1052–1057
   PubMed Web of Science ®Google Scholar
• Coll, J., A. Rives, M. C. Griñó, et al. (1987). Prevalence of Sjögren's syndrome in autoimmune diseases. Ann. Rheum. Dis. 46: 286–289
   PubMed Web of Science ®Google Scholar
• Avouac, J., C. Sordet, C. Depinay, et al. (2006). Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum. 54: 2243–2249
   PubMed Web of Science ®Google Scholar
• Ho Chan, W. S. (2010). Taiwan's healthcare report (2010). EPMA J. 1: 563–585
   PubMedGoogle Scholar
• Weng, M. Y., Y. T. Huang, M. F. Liu, et al. (2012). Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan. Ann. Rheum. Dis. 71: 524–527
   PubMed Web of Science ®Google Scholar
• Chung, W. S., C. L. Peng, C. L. Lin, et al. (2014). Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann. Rheum. Dis. 73: 1774–1780
   PubMed Web of Science ®Google Scholar
• Greenland, S., and K. J. Rothman (2008). Introduction to stratified analysis. In Modern Epidemiology. K. J. Rothman, S. Greenland, and T. L. Lash, eds. Lippincott Williams & Wilkins, Philadelphia. p. 252–282
   Google Scholar
• Feltsan, T., P. Stanko, and J. Mracna. (2012). Sjögren’s syndrome in present. Bratisl. Lek. Listy. 113: 514–516
   PubMed Web of Science ®Google Scholar
• Lu, M. C., W. Y. Yin, T. Y. Tsai, et al. (2013). Increased risk of primary Sjögren's syndrome in female patients with thyroid disorders: a longitudinal population-based study in Taiwan. PLoS One 8: e77210
   PubMedGoogle Scholar
• Matsushita, T., M. Hasegawa, K. Yanaba, et al. (2006). Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 54: 192–201
   PubMed Web of Science ®Google Scholar
• Vadacca, M., D. Margiotta, D. Sambataro, et al. (2010). BAFF/APRIL pathway in Sjögren syndrome and systemic lupus erythematosus: relationship with chronic inflammation and disease activity. Reumatismo. 62: 259–265
   PubMedGoogle Scholar
• Candon, S., J. E. Gottenberg, D. Bengoufa, et al. (2009). Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity. Ann. Rheum. Dis. 68: 1208–1212
   PubMed Web of Science ®Google Scholar
• Szodoray, P., P. Alex, M. V. Jonsson, et al. (2005). Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin. Immunol. 117: 168–176
   PubMed Web of Science ®Google Scholar
• Mariette, X., S. Roux, J. Zhang, et al. (2003). The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann. Rheum. Dis. 62: 168–171
   PubMed Web of Science ®Google Scholar
• Szodoray, P., S. Jellestad, P. Alex, et al. (2004). Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjögren's syndrome with a special emphasis on BAFF. J. Clin. Immunol. 24: 600–611
   PubMed Web of Science ®Google Scholar
• Groom, J., S. L. Kalled, A. H. Cutler, et al. (2002). Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J. Clin. Invest. 109: 59–68
   PubMed Web of Science ®Google Scholar
• Mariette, X., R. Seror, L. Quartuccio, et al. (2015). Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann. Rheum. Dis. 74: 526–531
   PubMed Web of Science ®Google Scholar
• Sato, S., M. Hasegawa, and K. Takehara. (2001). Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Dermatol. Sci. 27: 140–146
   PubMed Web of Science ®Google Scholar
• Katsifis, G. E., S. Rekka, N. M. Moutsopoulos, et al. (2009). Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am. J. Pathol. 175: 1167–1177
   PubMed Web of Science ®Google Scholar
• McGrath-Morrow, S., B. Laube, S. C. Tzou, et al. (2006). IL-12 overexpression in mice as a model for Sjögren lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L837–L846
   PubMed Web of Science ®Google Scholar
• Vosters, J. L., M. A. Landek-Salgado, H. Yin, et al. (2009). Interleukin-12 induces salivary gland dysfunction in transgenic mice, providing a new model of Sjögren's syndrome. Arthritis Rheum. 60: 3633–3641
   PubMed Web of Science ®Google Scholar
• Kimura-Shimmyo, A., S. Kashiwamura, H. Ueda, et al. (2002). Cytokine-induced injury of the lacrimal and salivary glands. J. Immunother. 25: S42–S51
   PubMed Web of Science ®Google Scholar
• Lessard, C. J., H. Li, I. Adrianto, et al. (2013). Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat. Genet. 45: 1284–1292
   PubMed Web of Science ®Google Scholar
• Scala, E., S. Pallotta, A. Frezzolini, et al. (2004). Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin. Exp. Immunol. 138: 540–546
   PubMed Web of Science ®Google Scholar
• Hulkkonen, J., M. Pertovaara, J. Antonen, et al. (2001). Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjögren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford) 40: 656–661
   PubMed Web of Science ®Google Scholar
• Maier-Moore, J. S., C. G. Horton, S. A. Mathews, et al. (2014). Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjögren's syndrome features in lupus-prone Sle1.Yaa mice. Arthritis Rheumatol. 66: 2521–2531
   Web of Science ®Google Scholar
• Rodriguez-Reyna, T. S., A. Hinojosa-Azaola, C. Martinez-Reyes, et al. (2011). Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity 44: 576–584
   PubMed Web of Science ®Google Scholar
• Martel, C., G. Gondran, D. Launay, et al. (2011). Active immunological profile is associated with systemic Sjögren's syndrome. J. Clin. Immunol. 31: 840–847
   PubMed Web of Science ®Google Scholar
• Toker, E., S. Yavuz, and H. Direskeneli. (2004). Anti-Ro/SSA and anti-La/SSB autoantibodies in the tear fluid of patients with Sjögren's syndrome. Br. J. Ophthalmol. 88: 384–387
   PubMed Web of Science ®Google Scholar
• Haga, H. J. (2002). Clinical and immunological factors associated with low lacrimal and salivary flow rate in patients with primary Sjögren's syndrome. J. Rheumatol. 29: 305–308
   PubMed Web of Science ®Google Scholar
• Daniels, T. E., D. Cox, C. H. Shiboski, et al. (2011). Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants. Arthritis Rheum. 63: 2021–2030
   PubMed Web of Science ®Google Scholar
• Jonsson, R., E. Theander, B. Sjöström, et al. (2013). Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA 310: 1854–1855
   PubMed Web of Science ®Google Scholar
• Miceli-Richard, C., E. Comets, P. Loiseau, et al. (2007). Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. Arthritis Rheum. 56: 3989–3994
   PubMed Web of Science ®Google Scholar
• Dieudé, P., M. Guedj, J. Wipff, et al. (2009). Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum. 60: 225–233
   PubMed Web of Science ®Google Scholar
• Beretta, L., B. Rueda, M. Marchini, et al. (2012). Analysis of Class II human leucocyte antigens in Italian and Spanish systemic sclerosis. Rheumatology (Oxford) 51: 52–59
   PubMed Web of Science ®Google Scholar
• Cruz-Tapias, P., A. Rojas-Villarraga, S. Maier-Moore, et al. (2012). HLA and Sjögren's syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun. Rev. 11: 281–287
   PubMed Web of Science ®Google Scholar
• Yi, L., J. C. Wang, X. J. Guo, et al. (2013). STAT4 is a genetic risk factor for systemic sclerosis in a Chinese population. Int. J. Immunopathol. Pharmacol. 26: 473–478
   PubMed Web of Science ®Google Scholar
• Korman, B. D., M. I. Alba, J. M. Le, et al. (2008). Variant form of STAT4 is associated with primary Sjögren's syndrome. Genes Immun. 9: 267–270
   PubMed Web of Science ®Google Scholar
• Ou, S. M., W. C. Fan, K. T. Chou, et al. (2014). Systemic sclerosis and the risk of tuberculosis. J. Rheumatol. 41: 1662–1669
   PubMed Web of Science ®Google Scholar